Adam D. Levy, Chief Financial Officer at Acrivon Therapeutics, Inc. (ACRV), sold 1,142 shares at $1.57 ($2K) on 2026-08-04, disclosed to the SEC on 2026-08-06.
Open-market sale of $2k ACRV by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.